Median overall survival time was 14.4 months with VYLOY + chemotherapy vs 12.2 months for chemotherapy alone
Some patients being treated in Trial 2 were assessed at 1 and 2 years. These results were not used to determine how well VYLOY performed and they only reflect the experience of these patients. Your experience may be different.
At 1 year
35% of patients on VYLOY + chemotherapy were progression-free
19% of patients on chemotherapy alone were progression-free
At 2 years
14% of patients on VYLOY + chemotherapy were progression-free
7% of patients on chemotherapy alone were progression-free
At 1 year
58% of patients on VYLOY + chemotherapy were still alive
51% of patients on chemotherapy alone were still alive
At 2 years
29% of patients on VYLOY + chemotherapy were still alive
17% of patients on chemotherapy alone were still alive
What are the possible side effects of VYLOY?
Support, tools, and resources are available for anyone receiving VYLOY